Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy.

Charles Dumontet, Sylvie Isaac, Pierre Jean Souquet, Françoise Bejui-Thivolet, Yves Pacheco, Nadine Peloux, Anthony Frankfurter, Richard Luduena, Maurice Perol

Research output: Contribution to journalArticle

114 Citations (Scopus)

Abstract

This study determined the prevalence and the prognostic value of the expression of microtubule components in tumors of 19 patients with non small cell lung cancer receiving taxane-based regimens. Patient samples were stained with antibodies directed against total beta tubulin, classes I, II and III beta tubulin isotypes, delta2 alpha tubulin, tau protein, and the P-gp protein involved in the classical multidrug resistance phenotype. All tumors were stained with pan-beta tubulin antibody and class I tubulin isotype. A majority of the tumor samples expressed class II and class III, although the percentage of positive cells varied significantly between tumors. delta2 alpha tubulin, tau protein and Pgp protein were found in only one tumor sample each. Progression-free survival was shorter (41 days) in patients whose tumors expressed high levels of class III tubulin isotype in comparison to patients with low levels (288 days, p = 0.02). There were 2 responses to chemotherapy among 9 patients (22%) with high levels of class III tubulin vs. 6 among 10 patients (60%) with low levels of expression (Fisher exact test: p = 0.11). These data suggest that high expression of class III tubulin by tumor cells is associated with poor prognosis in patients with NSCLC receiving a taxane-based regimen.

Original languageEnglish (US)
JournalBulletin du Cancer
Volume92
Issue number2
StatePublished - Feb 2005
Externally publishedYes

Fingerprint

Tubulin
Non-Small Cell Lung Carcinoma
Drug Therapy
Neoplasms
tau Proteins
taxane
Immunoglobulin Isotypes
Multiple Drug Resistance
Microtubules
Disease-Free Survival
Proteins
Cross-Sectional Studies
Phenotype
Antibodies

ASJC Scopus subject areas

  • Oncology

Cite this

Dumontet, C., Isaac, S., Souquet, P. J., Bejui-Thivolet, F., Pacheco, Y., Peloux, N., ... Perol, M. (2005). Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bulletin du Cancer, 92(2).

Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. / Dumontet, Charles; Isaac, Sylvie; Souquet, Pierre Jean; Bejui-Thivolet, Françoise; Pacheco, Yves; Peloux, Nadine; Frankfurter, Anthony; Luduena, Richard; Perol, Maurice.

In: Bulletin du Cancer, Vol. 92, No. 2, 02.2005.

Research output: Contribution to journalArticle

Dumontet, C, Isaac, S, Souquet, PJ, Bejui-Thivolet, F, Pacheco, Y, Peloux, N, Frankfurter, A, Luduena, R & Perol, M 2005, 'Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy.', Bulletin du Cancer, vol. 92, no. 2.
Dumontet C, Isaac S, Souquet PJ, Bejui-Thivolet F, Pacheco Y, Peloux N et al. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bulletin du Cancer. 2005 Feb;92(2).
Dumontet, Charles ; Isaac, Sylvie ; Souquet, Pierre Jean ; Bejui-Thivolet, Françoise ; Pacheco, Yves ; Peloux, Nadine ; Frankfurter, Anthony ; Luduena, Richard ; Perol, Maurice. / Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. In: Bulletin du Cancer. 2005 ; Vol. 92, No. 2.
@article{349b8dee5e2d432f9097196fd51a8db9,
title = "Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy.",
abstract = "This study determined the prevalence and the prognostic value of the expression of microtubule components in tumors of 19 patients with non small cell lung cancer receiving taxane-based regimens. Patient samples were stained with antibodies directed against total beta tubulin, classes I, II and III beta tubulin isotypes, delta2 alpha tubulin, tau protein, and the P-gp protein involved in the classical multidrug resistance phenotype. All tumors were stained with pan-beta tubulin antibody and class I tubulin isotype. A majority of the tumor samples expressed class II and class III, although the percentage of positive cells varied significantly between tumors. delta2 alpha tubulin, tau protein and Pgp protein were found in only one tumor sample each. Progression-free survival was shorter (41 days) in patients whose tumors expressed high levels of class III tubulin isotype in comparison to patients with low levels (288 days, p = 0.02). There were 2 responses to chemotherapy among 9 patients (22{\%}) with high levels of class III tubulin vs. 6 among 10 patients (60{\%}) with low levels of expression (Fisher exact test: p = 0.11). These data suggest that high expression of class III tubulin by tumor cells is associated with poor prognosis in patients with NSCLC receiving a taxane-based regimen.",
author = "Charles Dumontet and Sylvie Isaac and Souquet, {Pierre Jean} and Fran{\cc}oise Bejui-Thivolet and Yves Pacheco and Nadine Peloux and Anthony Frankfurter and Richard Luduena and Maurice Perol",
year = "2005",
month = "2",
language = "English (US)",
volume = "92",
journal = "Bulletin du Cancer",
issn = "1769-6917",
publisher = "John Libbey Eurotext",
number = "2",

}

TY - JOUR

T1 - Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy.

AU - Dumontet, Charles

AU - Isaac, Sylvie

AU - Souquet, Pierre Jean

AU - Bejui-Thivolet, Françoise

AU - Pacheco, Yves

AU - Peloux, Nadine

AU - Frankfurter, Anthony

AU - Luduena, Richard

AU - Perol, Maurice

PY - 2005/2

Y1 - 2005/2

N2 - This study determined the prevalence and the prognostic value of the expression of microtubule components in tumors of 19 patients with non small cell lung cancer receiving taxane-based regimens. Patient samples were stained with antibodies directed against total beta tubulin, classes I, II and III beta tubulin isotypes, delta2 alpha tubulin, tau protein, and the P-gp protein involved in the classical multidrug resistance phenotype. All tumors were stained with pan-beta tubulin antibody and class I tubulin isotype. A majority of the tumor samples expressed class II and class III, although the percentage of positive cells varied significantly between tumors. delta2 alpha tubulin, tau protein and Pgp protein were found in only one tumor sample each. Progression-free survival was shorter (41 days) in patients whose tumors expressed high levels of class III tubulin isotype in comparison to patients with low levels (288 days, p = 0.02). There were 2 responses to chemotherapy among 9 patients (22%) with high levels of class III tubulin vs. 6 among 10 patients (60%) with low levels of expression (Fisher exact test: p = 0.11). These data suggest that high expression of class III tubulin by tumor cells is associated with poor prognosis in patients with NSCLC receiving a taxane-based regimen.

AB - This study determined the prevalence and the prognostic value of the expression of microtubule components in tumors of 19 patients with non small cell lung cancer receiving taxane-based regimens. Patient samples were stained with antibodies directed against total beta tubulin, classes I, II and III beta tubulin isotypes, delta2 alpha tubulin, tau protein, and the P-gp protein involved in the classical multidrug resistance phenotype. All tumors were stained with pan-beta tubulin antibody and class I tubulin isotype. A majority of the tumor samples expressed class II and class III, although the percentage of positive cells varied significantly between tumors. delta2 alpha tubulin, tau protein and Pgp protein were found in only one tumor sample each. Progression-free survival was shorter (41 days) in patients whose tumors expressed high levels of class III tubulin isotype in comparison to patients with low levels (288 days, p = 0.02). There were 2 responses to chemotherapy among 9 patients (22%) with high levels of class III tubulin vs. 6 among 10 patients (60%) with low levels of expression (Fisher exact test: p = 0.11). These data suggest that high expression of class III tubulin by tumor cells is associated with poor prognosis in patients with NSCLC receiving a taxane-based regimen.

UR - http://www.scopus.com/inward/record.url?scp=14544302690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14544302690&partnerID=8YFLogxK

M3 - Article

C2 - 15749640

AN - SCOPUS:14544302690

VL - 92

JO - Bulletin du Cancer

JF - Bulletin du Cancer

SN - 1769-6917

IS - 2

ER -